Skip to main content

Table 3 Subgroup analyses for patients who underwent or did not undergo nephrectomy

From: Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma

Subgroups HR (95% CI) a P
Fuhrman grade
 Grade I 3.23 (1.22–8.53) 0.018
 Grade II 2.04 (1.51–2.75) < 0.001
 Grade III 3.48 (2.75–4.41) < 0.001
 Grade IV 1.53 (1.06–2.23) 0.024
Lymph node status
 N0 2.94 (2.38–3.64) < 0.001
 N1 1.71 (1.30–2.25) < 0.001
 NX 3.03 (1.71–5.35) < 0.001
Sarcomatoid feature
 Yes 2.01 (1.25–3.26) 0.005
 No 2.40 (1.99–2.89) < 0.001
 Unknown 3.13 (1.95–5.04) < 0.001
Bone metastasis
 Yes 2.46 (1.87–3.26) < 0.001
 No 2.43 (2.00–2.95) < 0.001
Brain metastasis
 Yes 2.16 (1.43–3.25) < 0.001
 No 2.46 (2.07–2.94) < 0.001
Liver metastasis
 Yes 3.09 (2.05–4.65) < 0.001
 sNo 2.36 (1.99–2.81) < 0.001
Lung metastasis
 Yes 2.50 (2.08–3.01) < 0.001
 No 2.22 (1.62–3.06) < 0.001
  1. a: Nephrectomy not recommended vs. nephrectomy recommended and performed
  2. Abbreviation: HR hazard ratio, 95% CI 95% confidence interval
\